ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0784

Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Abstract Number: 0785

Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
Abstract Number: 0786

Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
Abstract Number: 0787

Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Abstract Number: 0788

Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination – Results of 1-year Prospective Follow-up Study
Abstract Number: 0789

The Persistence of Anti-Spike Antibodies Following Two SARS-CoV-2 Vaccine Doses in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy Compared to Healthy Controls: A Prospective Cohort Study
Abstract Number: 0790

Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Abstract Number: 0791

Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Abstract Number: 0792

Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Abstract Number: 0793

Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Abstract Number: 0794

Impact of Vaccination on Post-acute Sequelae of SARS CoV-2 Infection in Patients with Rheumatic Diseases
Abstract Number: 0795

Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
Abstract Number: 0796

SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Abstract Number: 0797

Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease
Abstract Number: 0798

Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].